Trend in the Eradication Rates of<i>Helicobacter pylori</i>Infection Over the Last 10 Years in West Gyeonggi-do, Korea: A Single Center Experience

Park, Jong Seol; Park, Ji Eun; Oh, Byoung Soo; Yoon, Byung Wook; Kim, Hyun Ki; Lee, Jae Won; Kim, Nam Ho; Cho, Won Seok; Woo, Youngmin; Jahng, Jun Seop; Kim, Yong‐Sung

doi:10.4166/kjg.2017.70.5.232

Cited by 7 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is consistent with a recent study in Korea that reported no decrease in eradication rates of second-line BQT from 2003 to 2018 [ 20 ], although that study analyzed data from a 14-day regimen. Another study from 2006 to 2015 reported a similar result [ 21 ], but the number of subjects was relatively small (231 subjects). Interestingly, although there is a difference in the rate of antibiotic resistance in various geographic areas, BQT shows successful results and is recommended as a first- or second-line therapy in most areas [ 5 , 6 , 7 , 8 , 9 , 22 ].…”

Section: Discussionmentioning

confidence: 60%

Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates

Shin

Cho

et al. 2021

JCM

View full text Add to dashboard Cite

Background: Bismuth-containing quadruple therapy (BQT) consisting of a proton-pump inhibitor (PPI), bismuth, metronidazole and tetracycline is recommended as a second-line treatment for Helicobacter pylori (H. pylori) infection when PPI-based standard triple therapy (STT) consisting of a PPI, amoxicillin and clarithromycin is unsuccessful. The purpose of this study was to analyze the long-term results of BQT as a second-line therapy to determine its effectiveness. Methods: This study included 643 subjects who failed first-line STT and received 7 or 10–14 days of BQT as a second-line therapy. We retrospectively analyzed the annual H. pylori eradication rates, demographic factors and adverse events. Results: The overall eradication rates by intention-to-treat (ITT) and per-protocol (PP) analyses were 80.7% (519/643) and 93.3% (519/556), respectively. By PP analysis, the eradication rates for 2008–2011, 2012–2015, and 2016–2019 were 93.3%, 91.0%, and 96.4%, respectively (p = 0.145). There were no significant differences between the 7-day group and the 10–14-day group in both the ITT (79.7% vs. 86.0%, p = 0.148) and the PP analyses (92.7% vs. 96.6%, p = 0.187). A multivariate analysis showed that current smoking was associated with eradication failure. Eighty-nine subjects (16.0%) suffered adverse events, mainly gastrointestinal symptoms, but only six cases were severe. Conclusions: BQT as a second-line therapy is an effective treatment for H. pylori. Treatment for 10–14 days showed a higher eradication rate compared with a 7-day regimen, but not significantly.

show abstract

Section: Discussionmentioning

confidence: 60%

Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates

Shin

Cho

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…[6] The success rate of eradication therapy in South Korea has been reported to be around 80% recently. [78] However, a negative result on follow-up test after H. pylori treatment does not guarantee subsequent persistent eradication status in the future. To prevent progression of premalignant histological changes and recurrent peptic ulcer diseases, it is important to maintain H. pylori eradication status after successful treatment.…”

Section: Introductionmentioning

confidence: 99%

Rate and predictive factors of Helicobacter pylori recurrence: Analysis of a screening cohort

Nam

Ryu

Park

et al. 2019

Saudi J Gastroenterol

View full text Add to dashboard Cite

Background/Aim: The aim of the study was to identify the recurrence rate of Helicobacter pylori after successful eradication in an endemic area and investigate baseline and clinical factors related to the recurrence. Patients and Methods: H. pylori infected patients from a screening cohort of National Cancer Center between 2007 and 2012 were enrolled in the study. A total of 647 patients who were confirmed to be successfully eradicated were annually followed by screening endoscopy and rapid urease test. Median follow-up interval was 42 months. Annual recurrence rate of H. pylori was identified. Demographics, clinical factors, and endoscopic findings were compared between H. pylori recurrence group and persistently eradicated group (control group). Results: H. pylori recurrence was observed in 21 (3.25%) patients. Its annual recurrence rate was 0.91% (1.1% in males and 0.59% in females). Mean age was higher in the recurrence group than that in the control group (55.9 vs 50.7, P = 0.006). Median follow-up was shorter in the recurrence group than that in the control group (34 vs. 42.5 months, P = 0.031). In multivariate analysis, OR for H. pylori recurrence was 1.08 per each increase in age ( P = 0.012). Adjusted ORs for H. pylori recurrence were 0.20 (95% CI: 0.06–0.69) and 0.25 (95% CI: 0.08–0.76) in age groups of 50–59 years and less than 50 years, respectively, compared to the group aged 60 years or older. Conclusion: H. pylori recurrence rate in Korea is very low after successful eradication. Advanced age is at increased risk for H. pylori recurrence. Thus, H. pylori treatment for patients who are under 60 years of age is more effective, leading to maintenance of successful eradication status.

show abstract

Quadruple Therapy

Lee

2023

Helicobacter Pylori

View full text Add to dashboard Cite

Trend in the Eradication Rates ofHelicobacter pyloriInfection Over the Last 10 Years in West Gyeonggi-do, Korea: A Single Center Experience

Cited by 7 publications

References 25 publications

Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates

Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates

Rate and predictive factors of Helicobacter pylori recurrence: Analysis of a screening cohort

Quadruple Therapy

Contact Info

Product

Resources

About